PCJ.F ABEONA THERAPEUT. DL-01
- Market cap
- EUR 125M
- P/E
- -
- P/B
- 1.18x
- ROE
- -44.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is PCJ.F undervalued?
Graham numberThe Graham number of ABEONA THERAPEUT. DL-01 cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
ABEONA THERAPEUT. DL-01 fundamental analysis
No fundamental analysis for ABEONA THERAPEUT. DL-01 yet.
ABEONA THERAPEUT. DL-01 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About ABEONA THERAPEUT. DL-01
Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 to treat autosomal dominant optic atrophy. In addition,…
Full company profileABEONA THERAPEUT. DL-01 financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
ABEONA THERAPEUT. DL-01 annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 3.00M | 1.41M | 3.50M | 0.00 | 5.82M | 44.8M |
| Gross Profit | 3.00M | 964K | 1.90M | 0.00 | 2.40M | 28.0M |
| Operating Income | -57.4M | -45.3M | -48.2M | -64.2M | -89.4M | -66.2M |
| EBITDA | - | -34.4M | -50.6M | -56.6M | 78.6M | -49.9M |
| Net Income | -84.9M | -39.7M | -54.2M | -63.7M | 71.2M | -56.1M |
| EPS | -14 | -2.24 | -2.04 | -1.40 | 1.29 | -0.98 |
| Balance Sheet | ||||||
| Total Assets | 79.6M | 64.2M | 64.0M | 109M | 220M | 172M |
| Total Liabilities | 37.2M | 37.5M | 49.2M | 64.9M | 60.4M | 46.0M |
| Shareholders' Equity | 42.4M | 26.8M | 14.8M | 44.0M | 159M | 126M |
| Cash & Short-term Investments | 32.9M | 14.2M | 14.5M | 23.4M | 78.4M | 66.3M |
| Cash Flow | ||||||
| Operating Cash Flow | -65.7M | -43.5M | -37.0M | -56.0M | -76.3M | -60.8M |
| Capital Expenditure | 4.15M | 130K | 331K | 2.45M | 7.98M | 2.18M |
| Free Cash Flow | -69.8M | -43.6M | -37.3M | -58.5M | -84.3M | -63.0M |
| Ratios | ||||||
| ROE | -200.5% | -148.3% | -365.5% | -144.7% | 44.7% | -44.6% |
| ROA | -106.7% | -61.8% | -84.7% | -58.5% | 32.4% | -32.6% |
| Net Profit Margin | -2,831.2% | -2,807.4% | -1,548.2% | - | 1,223.1% | -125.3% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
ABEONA THERAPEUT. DL-01 dividends
ABEONA THERAPEUT. DL-01 has not paid dividends in the last 5 fiscal years.
Last stock split: 1:25 on Jul 5, 2022.
Who owns ABEONA THERAPEUT. DL-01
- Insiders 12.30%
- Institutions 72.24%
- Public & others 15.46%
- Shares outstanding 61.6M
- Free float 36.2M
ABEONA THERAPEUT. DL-01 company profile
- Company name
- ABEONA THERAPEUT. DL-01
- Ticker
- PCJ.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 226
- Fiscal year end
- December
- Address
- 6555 Carnegie Avenue, Cleveland, OH, United States, 44103
- Phone
- 646 813 4701
- Website
- abeonatherapeutics.com
About ABEONA THERAPEUT. DL-01
Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 to treat autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was founded in 1974 and is headquartered in Cleveland, Ohio.
ABEONA THERAPEUT. DL-01 management
10- Dr. Vishwas Seshadri M.B.A., Ph.D.President, CEO & Director · born 1976
- Mr. Joseph Walter Vazzano CPAChief Financial Officer · born 1984
- Dr. Brendan M. O'Malley J.D., Ph.D.Chief Legal Officer · born 1969
- Mr. Brian Kevany Ph.D.Chief Technical & Scientific Officer
- Mr. Gregory GinVice President of Investor Relations & Corporate Communications
- Ms. Gianine EspositoSenior VP & Chief People Officer
- Mr. Jon VossVP & Head of Quality · born 1960
- Dr. Madhav Vasanthavada M.B.A., Ph.D.SVP, Chief Commercial Officer & Head of Business Development · born 1979
- Mr. Carl DennySenior Vice President of Regulatory Affairs
- Ms. Megan CallanVice President & Head of Quality